» Authors » Isabelle Bureau

Isabelle Bureau

Explore the profile of Isabelle Bureau including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 114
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Arnaud L, Fabry-Vendrand C, Todea R, Vidal B, Cottin J, Bureau I, et al.
Lupus Sci Med . 2025 Feb; 12(1). PMID: 39965876
Background: Oral glucocorticoids (OCS) remain one of the most important treatments for SLE but are associated with damage. Evidence regarding the real-world use of OCS in nationwide SLE populations is...
2.
Arnaud L, Fabry-Vendrand C, Todea R, Vidal B, Cottin J, Bureau I, et al.
Joint Bone Spine . 2024 Dec; 92(3):105827. PMID: 39622366
Objectives: Data on the economic consequences of systemic lupus erythematosus (SLE) and lupus nephritis (LN) are scarce in Europe. We aimed to estimate the total direct costs attributable to SLE...
3.
Gourdy P, Darmon P, Borget I, Emery C, Bureau I, Detournay B, et al.
Diabetes Ther . 2024 Jul; 15(9):2131-2132. PMID: 39008238
No abstract available.
4.
Gourdy P, Darmon P, Borget I, Emery C, Bureau I, Detournay B, et al.
Diabetes Ther . 2024 Apr; 15(6):1349-1360. PMID: 38642261
Introduction: Second-generation basal insulins like glargine 300 U/mL (Gla-300) have a longer duration of action and less daily fluctuation and interday variability than first-generation ones, such as glargine 100 U/mL...
5.
Loubet P, Fernandes J, de Pouvourville G, Sosnowiez K, Elong A, Guilmet C, et al.
J Clin Virol . 2024 Jan; 171:105635. PMID: 38215557
Background: Respiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTI) that may lead to hospitalization or death. The present study aimed to assess the burden of RSV infections in...
6.
Pourcher V, Gourmelen J, Bureau I, Bouee S
PLoS One . 2020 Dec; 15(12):e0243529. PMID: 33332394
Objectives: As people living with HIV (PLHIV) age, the burden of non-HIV related comorbidities increases resulting in additional healthcare costs. The present study aimed to describe the profile, the prevalence...
7.
Bourdin A, Fabry-Vendrand C, Ostinelli J, Ait-Yahia M, Darnal E, Bouee S, et al.
J Allergy Clin Immunol Pract . 2019 Jan; 7(5):1477-1487. PMID: 30685573
Background: Severe asthma (SA) is defined by treatment intensity. The availability of national databases allows accurate estimation of the prevalence, long-term outcomes, and costs of SA. Objective: To provide accurate...
8.
Dallongeville J, Sacher F, Bouee S, Emery C, Bureau I, Gourmelen J, et al.
Therapie . 2018 Aug; 73(6):449-460. PMID: 30075870
Background: Little is known about the utilization of rivaroxaban in real life treatment settings in France. Aims: Objectives of this study were to describe the conditions of use and treatment...
9.
Boulias C, Ismail F, Phadke C, Bagg S, Bureau I, Charest S, et al.
Arch Phys Med Rehabil . 2018 May; 99(11):2183-2189. PMID: 29803825
Objective: To create a consensus statement on the considerations for treatment of anticoagulated patients with botulinum toxin A (BoNTA) intramuscular injections for limb spasticity. Design: We used the Delphi method....
10.
Charbonnel B, Simon D, Dallongeville J, Bureau I, Dejager S, Levy-Bachelot L, et al.
Pharmacoecon Open . 2018 Apr; 2(2):209-219. PMID: 29623622
Objectives: Our objects was to estimate the direct healthcare costs of type 2 diabetes mellitus (T2DM) in France in 2013. Methods: Data were drawn from a random sample of ≈600,000...